Medicure Acquires Exclusive License to Sell and Market Branded Cardiovascular Drug in the U.S. WINNIPEG, Dec. 14, 2017/CNW/ - Medicure Inc. (`Medicure` or the `Company`) (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that, through its subsidiary, Medicure International Inc., it has acquired, from a large multinational pharmaceutical company, an exclusive license to sell and market a branded cardiovascular drug, for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia, in the United Statesand its territories. The licensing agreement is for a term of seven years with extensions to the term available. The cardiovascular drug was approved earlier in 2017...
|
